Cyclosporin H: A Novel Anti-Inflammatory Therapy with Applications for Covid-19 Patients



Salwa A. Elgebaly, Ph.D. Founder & CEO, Nour Heart, Inc. Vienna, Virginia, U.S. **Department of Surgery, Univ. of Connecticut** School of Medicine, Farmington, CT, U.S.







Publications



Nourexin-4 A Novel Antiinflammatory Therapy for Influenza Flu (52.1)

Salwa Elgebaly, Daniel Perez, Kathleen Sullivan, Craig Whitaker, Stephanie Caspe, Qiao Yi and Donald Kreutzer

J Immunol April 1, 2010, 184 (1 Supplement) 52.1;

Journal of the Egyptian Society of Parasitology, Vol. 47, No. 1, April 2017 J. Egypt. Soc. Parasitol. (JESP), 47(1), 2017: 25 - 33

CYCLOSPORIN H: A NOVEL ANTI-INFLAMMATORY THERAPY FOR INFLUENZA FLU PATIENTS

SALWA A. ELGEBALY^{1*}, TAMER ELBAYOUMI², and DONALD L. KREUTZER³

2020 Citations in Covid-19 Patients Papers

Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review. Campbell CM, Guha A, Haque T, Neilan TG, Addison D J Clin Med, 9(9), 11 Sep 2020 Cited by: 1 article | PMID: 32932930 | PMCID: PMC7565788

Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19). Cure E, Kucuk A, Cumhur Cure M Rheumatol Int, 40(7):1177-1179, 15 May 2020 Cited by: 10 articles | PMID: 32415310 |

PMCID: PMC7227450

Cyclosporine: an old weapon in the fight against coronaviruses. Molyvdas A, Matalon S Eur Respir J, 56(5), 26 Nov 2020 Cited by: 2 articles | PMID: 32732332 | PMCID: PMC7397953

Outline

3

Cyclosporin H and Lethal H1N1 Swine Influenza Flu Virus

- Cytokine Storm
- Nourin and Cytokine Storm
- Cyclosporin H Inhibits Nourin and Lung Inflammation

Cyclosporin H and Covid-19 Patients

Cyclosporin H and Cardiac Inflammation in Covid-19 Patients

Conclusions

A Proposed Mechanism for Influenza Flu Virus Infection in Lungs (Corona Virus)

Stages of Viral Infection:

- 1. Adhesion
- 2. Replication
- 3. Activation
- Virus-induced cytokine storm leads to acute respiratory distress syndrome (ARDS)



What is a Cytokine Storm? "Role in Tissue Necrosis"

5

Viral and Bacterial Infection:

Immune Protection:

Immune response results in resolution and recovery &

Immunopathology:

Viral and bacterial-Induced overactive inflammatory response, resulting in cytokine storm (**CS**)







Immune protection Resolution and Recovery

Immunopathology Severe Disease and Death

CS

Modified John C. Kash, Ph.D. NIH/NIAID

Current Therapeutic Approaches "Targeting Virus, Leukocytes and Mediators"



6

Modified N Engl J Med 2005; 352:1839-1842

Cyclosporin H (CsH): A Novel Anti-inflammatory "Inhibitor of Inflammatory Mediator, Nourin"

7



Modified N Engl J Med 2005; 352:1839-1842

Phases of Development of Cytokine Storm that Leads to Acute Respiratory Distress Syndrome (ARDS)

Triphasic ARDS – 3 Weeks:

- 1. Viral Replication Phase Week 1
 - First 7 days
 - Low levels of Cytokines & Leukocytes
- 2. Immune Hyperactive Phase Week 2
 - Second 7 to 14 days
 - High Cytokine Storm + Inflammation
- 3. Pulmonary Destruction Phase Week 3
 - Third 14 to 21 days
 - Tissue Necrosis

Nourin & Cytokine Storm Mediators:

Leukocyte Chemotaxis, Adhesion & Activation

Nourin & Development of Cytokine Storm



What is Nourin?

A Novel "Injury Response" Molecule!

NOURIN:

- Rapidly released by <u>local tissues</u> in response to injury
- Potent inflammatory mediator (Review: Elgebaly 2017 & 2019)
- Shares 3 KDa formyl peptide, but differs in isoelectric point
- Binds to formyl peptide receptor (FPR) on leukocytes and vascular endothelial cells (VECs)
- Stimulates leukocyte chemotaxis, adhesion and activation
- It is associated with acute and chronic tissue inflammation
- Activates human leukocytes and VECs to express:
 - Cytokine storm mediators
 - Digestive enzymes
 - Free radicals



Elgebaly SA, et al. Expert Review of Cardiovascular Therapy. 2019 ,Sep 2;17(9):683-97, REVIEW Elgebaly SA, et al. J Eg Soc Parasitol. 2017;47(1):27–35 Elgebaly SA, et al. Amer. Assoc. of Immunologists. 2010; May 97, 52 Elgebaly SA, et al. *Circulation. 2020; 142*, A13051-A13051 Elgebaly SA, et al. *Circulation. 2020; 142*, A13103-A13103 Elgebaly SA, et al. *Biomolecules. 2021;* 11, 368 Elgebaly SA, et al. *Diagnostics. 2021;* 11, 703 Elgebaly SA, et al. *Int. J. Mol. Sci. 2021;* 22, 3575

Nourin Stimulates Expression of Cytokine Storm Mediators by "Neutrophils" & "VECs"

Neutrophils (24 hours):

- > Chemotactic factor, IL-8
- > Adhesion molecule, LECAM-1
- > Free radicals, superoxide anion
- Digestive enzymes:
 - N-acetyl-B-glucosaminidase
 - Collagenase
 - Gelatinases (matrix remodelling)

Aortic Vascular Endothelial Cells (24 hours):

- > Chemotactic factor, IL-8
- Adhesion molecule, ICAM-1
- Adhesion molecule, ELAM-1



Nourin Stimulates Expression of Cytokine Storm Mediators by Human "Monocytes"

Monocytes

(4 hours)

Inflammatory Mediator	Treatment	
	Nourin	Control Media
Interleukin-8 (ng/mL)	12,000	2,000
Interleukin-1β (pg/mL)	400	10
TNF-α (pg/mL)	400	<10

IL-8, IL-1β and TNF-α:	Key mediators in cytokine storm
TNF-α:	Key stimulant of apoptosis
	TNF-α concentration in excess of 1 ng/ml is frequently predictive of a lethal outcome

12

What Are Nourin Antagonists?

- Competitive antagonists inhibit Nourin chemotactic activity and reduce tissue inflammation:
 - Cyclosporin H
 - Spinorphin
 - Soluble FPR fragment 17 aa loop peptide
- A bioenergetic compound, Cyclocreatine Phosphate (CCrP) prevents tissue injury, reduces Nourin intracellular formation and circulating levels, resulting in reduction of tissue inflammation



Elgebaly SA, et al. Expert Review of Cardiovascular Therapy. 2019 ,Sep 2;17(9):683-97, REVIEW Elgebaly SA, et al. J Eg Soc Parasitol. 2017;47(1):27–35 Elgebaly SA, et al. Amer. Assoc. of Immunologists. 2010; May 97, 52 Elgebaly SA, et al. *Int. J. Mol. Sci. 2021*; 22, 3575

What is Cyclosporin H? "Inhibitor of Bacterial Product 1 – FMLP"

- Cyclosporin H (CsH) is L isomer of Cyclosporin A
- Cyclosporin H is a potent anti-inflammatory
- Cyclosporin A is an immunosuppressant. In mice infected with influenza flu virus, CsA treatment:
 - Increased virus load in lungs
 - Delayed the rate of viral elimination
 - Increased mortality
- CsH and FMLP; a Nourin-related bacterial product
 - CsH is a competitive antagonist of formyl peptides (FP) on leukocyte FPR
 - Inhibits FMLP-induced neutrophil chemotaxis





Elgebaly SA, et al. J Eg Soc Parasitol. 2017;47(1):27–35 Elgebaly SA, et al. Amer. Assoc. of Immunologists. 2010; May 97, 52

14

Other Anti-inflammatory Activity of CsH "Inhibitor of Bacterial Product 2 - Staph. aureus Toxin"



<u>Sepsis</u>

- MRSA: Methicillin Resistant *Staph. aureus*
 - Toxins released by S. aureus are formyl peptides: <u>PSMα3</u> (J. Nature Medicine Vol 11, 1-5, 2007)
 - > S. aureus formyl peptides are potent inflammatory mediators
 - Removal of S. aureus formyl peptide toxins increased survival
- CsH inhibits neutrophil chemotaxis by *S. aureus* toxin, PSMα3

CsH (Nourexin-4) (5x10-4 M - 5x10-5 M) Inhibition of Chemotactic Activity Induced In-vitro by *S. aureus*-derived PSMa3



Elgebaly SA, et al. J Eg Soc Parasitol. 2017;47(1):27–35 Elgebaly SA, et al. Amer. Assoc. of Immunologists. 2010; May 97, 52

15

Cyclosporin H and Viral Infection



Lethal H1N1 Swine Influenza Flu Virus

Hypothesis

1. Influenza flu virus infection of airway epithelial cells will trigger cell injury and the release of cell-derived pro-inflammatory mediators, including the formyl peptide, Nourin.

2. The Nourin antagonist, CsH will inhibit Nourin activity and initial lung inflammation in mice infected with the lethal H1N1 Swine influenza flu virus for 5 days (CS 3 to 8 days).



Experimental Plan 1:

To confirm Nourin Release in vitro and in vivo
Inhibition of Nourin Activity by CsH

Lethal H1N1 Swine Influenza Flu Virus

- Release of Nourin by <u>cultured epithelial cells</u> infected with laboratory influenza virus (PR8) for 24 h; *inhibition by CsH*
- Detection of Nourin in serum of <u>mice</u> infected with lethal H1N1 Swine influenza flu virus for 6 h; *inhibition by CsH*
- Detection of Nourin in plasmas of <u>patients</u> with severe, moderate H1N1 Swine influenza flu virus and mild RSV; inhibition by CsH







*Results:*1. Cultured Epithelial Cells Infected with PR8 Influenza Virus

Cell Culture



- Nourin is rapidly released by 1 h after PR8 virus-infected epithelial cells
- Nourin release continued for 24 h
- Cyclosporin H (Nourexin-4) (5x10-6 M) inhibited Nourin-induced neutrophil chemotactic activity to control value



*Results:*2. Mice Infected with H1N1 Swine Influenza Flu Virus for 6 hours





- Nourin detected in serum <u>6 h</u> after infection with H1N1 Swine influenza flu virus (nasal inoculation)
- CsH (5x10-6 M) inhibited Nourin-stimulated neutrophil chemotaxis to control level in mice infected for <u>6 h</u>



*Results:*3. Nourin Levels in Patients with H1N1 Swine Influenza Flu Virus

Patients



Dr. Kathleen Sullivan, PA

High level of Nourin was detected in plasma samples collected from "<u>severely</u>" ill patients infected with H1N1 Swine influenza flu virus (ICU patients)

- To a lesser extent, Nourin level in hospitalized "<u>moderate</u>" influenza patients
- Low level of Nourin was detected in plasma samples collected from patients with "<u>low</u>" respiratory syncytial virus (RSV) infection



19

Elgebaly SA, et al. Amer. Assoc. of Immunologists. 2010; May 97, 52

*Results:*4. CsH Inhibits Nourin in Patients' Plasmas

Patients



The Nourin competitive antagonist, Cyclosporin H at 10-5 M significantly inhibited neutrophil chemotaxis induced by host-derived Nourin as detected in all influenza patients' samples



Experimental Plan 2:

- Effect of CsH on Lung Inflammation

<u>Mice</u>

- Mice infected with H1N1 Swine influence flu virus were treated for 5 days with:
 - ➢ H1N1 + CsH (n=5)
 - H1N1 + CsH vehicle (n=4)
 - H1N1 + Saline (n=5)



- Healthy mice were treated with saline (n=4) for 5 days
- Analysis at day 5:
 - Viral titer in lungs
 - Body weight
 - Lung inflammation (histology)

*Results:*5. CsH Did <u>Not</u> Increase Viral Titer in Lungs





- Unlike Cyclosporin A, CsH did <u>not</u> increase viral load in the infected mice at day 5, when compared to H1N1 control
- CsH is not an immunosuppressant
- CsH does not target the influenza virus
- CsH did not change body weight compared to H1N1 saline control mice



*Results:*6. CsH Reduces Mouse Lung Inflammation at Day 5



Saline H1N1/Saline treated lung mouse – HIGH inflammation

<u>Cyclosporin H</u> H1N1/CsH treated lung mouse – **REDUCED** inflammation

Summary

<u>Nourin</u>

- **Released "early" after viral infection and is critical for development of cytokine storm**
- Plays a key role in viral-induced lung inflammation
- Plasma level correlates with disease severity in patients infected with H1N1 Swine influenza flu virus

24

Cyclosporin H



- Significantly reduced Nourin activity and lung inflammation induced by H1N1 Swine influenza flu virus
- Not an immunosuppressant (did not reduce mice immunity thus, no increase in viral replication)
- Does not target the influenza virus, but targets Nourin
- Completely blocked chemotactic activity induced by the lethal bacterial S. aureus toxin, PSMα3

25

Cyclosporin H and Covid-19 Patients

Cyclosporin H and Lung Inflammation





SARS-CoV-2 Virus

Cyclosporin H and Heart Inflammation



Cardiac Inflammation in 60% of COVID-19 Patients (JAMA Cardiology 2020)

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

<u>Valentina O. Puntmann, MD, PhD¹</u>; <u>M. Ludovica Carerj, MD^{1,2}</u>; et al. *JAMA Cardiol.* 2020;5(11):1265-1273. doi:10.1001/ jamacardio.2020.3557



National Geographic 2d · €

The CDC has convened an emergency meeting of its advisory committee on June 18 to discuss rare reports of heart inflammation among people who have received the Pfizer and Moderna vaccines.

26



NATIONALGEOGRAPHIC.COM Latest: CDC to hold emergency meeting over rare cases of heart inflammation after vaccination

Cardiac Inflammation

Myocardial Inflammation **MYOCARDITIS** Causes Symptoms Viruses Weakness e.g. Coxsackie B-Virus Shortness of breath Cardiac arrhythmias Bacteria healthy heart myocarditis

> Cyclosporin H will potentially inhibit cardiac inflammation in Covid-19 patients

27

Cardiac-derived Nourin is released by injured myocardium and associated with cardiac inflammation

Elgebaly SA, et al. Expert Review of Cardiovascular Therapy. 2019, Sep 2;17(9):683-97 - REVIEW Elgebaly SA, et al. *Circulation. 2020; 142*, A13051-A13051 Elgebaly SA, et al. *Circulation. 2020; 142*, A13103-A13103 Elgebaly SA, et al. *Biomolecules. 2021;* 11, 368 Elgebaly SA, et al. *Diagnostics. 2021;* 11, 703 Elgebaly SA, et al. *Int. J. Mol. Sci. 2021;* 22, 3575

Cardiac Inflammation Associated with Hypertrophic Cardiomyopathy





Cardiac Inflammation Associated with Heart Failure





Conclusions

Nourin is an <u>novel "early" lung-derived inflammatory biomarker</u>:

- Can diagnose and monitor patients with influenza flu virus infection
- Can stratify "severity" of infection with higher expression in ICU severely ill patients compared to moderate hospitalized and mild
- Cyclosporin H is a potential novel <u>anti-inflammatory</u> therapy for influenza flu virus patients, including <u>COVID-19</u> to:
 - Reduce lung and heart inflammation
 - "Early" protect against cytokine storm
- By controlling excessive host inflammatory responses, Cyclosporin H will potentially <u>increase survival</u>



30

SARS-CoV-2 Virus

Conclusions

- Cyclosporin H targets Nourin and <u>not the virus</u>, thus, it will not:
 - Have <u>time restriction</u> like Tamiflu and Remdesivir (first one to two days of infection)
 - Develop <u>vaccine</u> resistance to "new" strains of flu viruses and "existing" viruses with mutations
- Cyclosporin H is <u>not an immunosuppressant</u>, thus, will not:
 - Affect the host defense immune system
 - Subject patients to additional infections and cancer



31

SARS-CoV-2 Virus

Cyclosporin H: A Novel Anti-inflammatory "Inhibitor of Inflammatory Mediator, Nourin"



Modified Osterholm MT, N Engl J Med 2005; 352:1839-1842

Thank You.

33



Prof. Salwa Ahmed Elgebaly selgebaly@nourheart.com